DEF 14A: Aptevo Therapeutics Seeks Stockholder Approval for Stock Issuance, Warrant Amendments, and Reverse Stock Split

Aptevo Therapeutics is holding a special meeting to seek stockholder approval for a stock issuance, warrant amendments, a reverse stock split, and adjournment authorization.

Summary

• Aptevo Therapeutics Inc. is convening a special meeting of stockholders on October 25, 2024, to vote on three proposals.
• Proposal 1 seeks approval for the issuance of more than 19.99% of the company's outstanding common stock upon the exercise of common warrants, including an exercise price adjustment provision, and to approve amendments to certain existing warrants to include the same provisions and repricing.
• Proposal 2 involves approving an amendment to the company's certificate of incorporation to effect a reverse stock split of the common stock at a ratio between 1-for-5 and 1-for-37, with the specific ratio and timing to be determined by the board of directors.
• Proposal 3 requests authorization to adjourn the meeting to solicit additional proxies if there are insufficient votes for Proposal 1 or Proposal 2.
• The board of directors recommends voting 'FOR' all three proposals.
• The record date for the Special Meeting is September 13, 2024.
• The company completed a registered direct offering on September 18, 2024, issuing 9,090,910 shares and warrants to purchase up to 18,181,820 shares, with gross proceeds of approximately $3.0 million.
• The company intends to use the net proceeds for clinical development, working capital, and general corporate purposes.
• The company received a letter from Nasdaq on June 25, 2024, stating that the company was not in compliance with the minimum bid price requirement of $1.00 per share.
• The company has until December 23, 2024, to regain compliance.
• If the reverse stock split is not approved, the company may not be able to regain compliance with Nasdaq listing requirements, potentially leading to delisting.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While the company has secured additional funding, it is also facing potential delisting from Nasdaq, which creates uncertainty and risk for investors. The need for a reverse stock split indicates underlying financial challenges.

Positives

• The registered direct offering completed on September 18, 2024, raised approximately $3.0 million, providing capital for clinical development and operations.
• Approval of the reverse stock split could help the company regain compliance with Nasdaq listing requirements, avoiding potential delisting.
• The board of directors is actively addressing the Nasdaq bid price deficiency by proposing the reverse stock split.
• The company has engaged Roth Capital Partners, LLC to provide exclusive financial services in connection with these transactions.

Negatives

• Failure to approve the stock issuance and warrant proposal would render the warrants unexercisable and could hinder future financing efforts.
• The company received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement.
• If the reverse stock split is not approved, the company may face delisting from Nasdaq, which could adversely affect the stock's liquidity and market price.
• The issuance of shares upon exercise of the warrants will dilute existing stockholders' ownership.
• The reverse stock split could decrease the liquidity of the common stock and result in higher transaction costs.

Risks

• Failure to obtain stockholder approval for the stock issuance and warrant proposal could limit the company's access to future capital.
• The reverse stock split may not increase the stock price sufficiently to maintain Nasdaq compliance.
• Delisting from Nasdaq could reduce the visibility, liquidity, and value of the company's common stock.
• The market price of the common stock may decrease even if the reverse stock split is implemented.
• The reverse stock split could decrease the liquidity of the common stock and result in higher transaction costs.

Future Outlook

The company expects to use the net proceeds from the recent transactions for the continued clinical development of its product candidates, working capital, and other general corporate purposes. The company may have difficulty finding alternative sources of capital to fund its operations in the future on terms favorable to it or at all if the Stock Issuance and Warrant Proposal is not approved.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. The company is trying to avoid the negative consequences of delisting, such as reduced liquidity and investor interest, which are common concerns in the biotech industry where maintaining access to capital is crucial.

Comparison to Industry Standards

• Many companies facing Nasdaq delisting due to the Bid Price Requirement have implemented reverse stock splits.
• Comparable companies in the biotech sector, such as Geron Corporation and BioTime, Inc., have previously used reverse stock splits to regain compliance with Nasdaq listing requirements.
• The success of a reverse stock split in maintaining compliance and improving stock performance varies, with some companies experiencing sustained price increases while others see their stock price decline again.

Stakeholder Impact

• Shareholders face potential dilution from the issuance of new shares upon warrant exercise.
• Shareholders may experience a change in the market value and liquidity of their shares depending on the outcome of the reverse stock split and Nasdaq compliance.
• Employees' stock options and equity awards will be adjusted proportionally based on the reverse stock split ratio.
• The company's ability to raise capital and fund its operations could be affected by the outcome of the stockholder votes.

Next Steps

• Stockholders will vote on the proposals at the Special Meeting on October 25, 2024.
• The board of directors will determine whether to implement the reverse stock split and at what ratio, based on market conditions and other factors.
• The company will file a Certificate of Amendment with the Secretary of State of the State of Delaware if the reverse stock split is approved and implemented.
• The company will continue to monitor its stock price and compliance with Nasdaq listing requirements.

Key Dates

Keywords

reverse stock split, stock issuance, warrants, Nasdaq, compliance, dilution, offering, Aptevo Therapeutics, stockholders, proxy